




CV Template of KATRD International Conference 2021

Name	In-Jae Oh			
First Name	In-Jae	Last Name	Oh	
Country	Korea			
Organization	Chonnam National University Hwasun Hospital			
Current Position	Professor			

Educational Background

2002-2008 PhD from Chonnam National University
1999-2001 Master's degree from Chonnam National University
1992-1998 Bachelor's degree from Chonnam National University

Professional Experiences

2017 – Professor of Chonnam National University Medical School
present
2000 Visiting professor of Korea Advanced Institute of Science and Technology
2012-2017 Associate professor of Chonnam National University Hwasun Hospital
2007-2012 Assistant professor of Chonnam National University Hwasun Hospital
2006-2007 Fellowship from Chonnam National University Hospital (CNUH)
2003-2006 Flight surgeon of Republic of Korean Army
1999-2003 Resident of department of Internal Medicine in CNUH

Professional Organizations

- Associate editor of Cancer Research and Treatment
- Editorial board member of Tuberculosis and Respiratory Disease, Yonsei Medical Journal, Journal of Thoracic Disease, Translational Cancer Research, and Journal of Clinical Medicine
- Member of The Korean Academy of Tuberculosis and Respiratory Diseases, The Korean Association of Internal Medicine, International Association of Study of Lung Cancer, The Korean Association of Lung Cancer, Korean Cancer Association, The Korean Society of Critical Care Medicine



Main Scientific Publications

1. Baek E-T, Yang HJ, Kim SH, Lee GS, **Oh I-J**, Kang S-R, et al. Survival time prediction by integrating cox proportional hazards network and distribution function network. BMC Bioinformatics. 2021;22(1):192.
2. Kim M-S, Park H-Y, Kho B-G, Park C-K, **Oh I-J**, Kim Y-C, et al. Artificial intelligence and lung cancer treatment decision: agreement with recommendation of multidisciplinary tumor board. Transl Lung Cancer Res. 2020;9(3):507-14.
3. Kho BG, Park HY, Cho HJ, Park CK, Kim YC, Yun JS, **Oh I-J**, et al. Glutathione Peroxidase 3 as a Biomarker of Recurrence after Lung Cancer Surgery. J Clin Med. 2020;9(12).
4. **Oh IJ**, Kim KS, Kim YC, Park JY, Yoo KY, Do SH, et al. Altered Hypothalamus-Pituitary-Adrenal Axis Function: A Potential Underlying Biological Pathway for Multiple Concurrent Symptoms in Patients With Advanced Lung Cancer. Psychosomc Med. 2019;81(1):41-50.
5. Novello S, Mazieres J, **Oh IJ**, de Castro J, Migliorino MR, Helland A, et al. Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study. Ann Oncol. 2018;29(6):1409-16.
6. Sampson JN, Wheeler WA, Yeager M, Panagiotou O, Wang Z, Berndt SI, **Oh IJ**, et al. Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types. J Natl Cancer Inst. 2015;107(12):d1v279.
7. Kim Y, Hammerman PS, Kim J, Yoon JA, Lee Y, Sun JM, **Oh IJ**, et al. Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patients. J Clin Oncol. 2014;32(2):121-8.
8. Lan Q, Hsiung CA, Matsuo K, Hong Y-C, Seow A, Wang Z, **Oh IJ**, et al. Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia. Nat Genet. 2012; advance online publication.
9. Kim SO, Jeong JY, Kim MR, Cho HJ, Ju JY, Kwon YS, **Oh IJ**, et al. Efficacy of gemcitabine in patients with non-small cell lung cancer according to promoter polymorphisms of the ribonucleotide reductase M1 gene. Clin Cancer Res. 2008;14(10):3083-8.